CURIS

Curis Lifesciences Share Price

 

 

Start SIP in CURIS

Start SIP

Performance

  • Low
  • ₹118
  • High
  • ₹120
  • 52 Week Low
  • ₹107
  • 52 Week High
  • ₹148
  • Open Price₹120
  • Previous Close₹123
  • Volume9,000
  • 50 DMA-
  • 100 DMA-
  • 200 DMA-

Investment Returns

  • Over 1 Month + 2.74%
  • Over 3 Month -7.62%
  • Over 6 Month -7.62%
  • Over 1 Year -7.62%

Smart Investing Starts Here Start SIP with Curis Lifesciences for Steady Growth!

Invest Now

Curis Lifesciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 15.7
  • PEG Ratio
  • -
  • Market Cap Cr
  • 96
  • P/B Ratio
  • 4.5
  • Average True Range
  • 5.81
  • EPS
  • 7.55
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.92
  • RSI
  • 47.46
  • MFI
  • 55.76

Curis Lifesciences Financials

Curis Lifesciences Technicals

EMA & SMA

Current Price
₹118.25
-4.5 (-3.67%)
pointer
  • Bearish Moving Average 9
  • Bullish Moving Average 0
  • 20 Day
  • ₹123.99
  • 50 Day
  • -
  • 100 Day
  • -
  • 200 Day
  • -

Resistance and Support

120.23 Pivot Speed
  • R3 132.82
  • R2 127.78
  • R1 125.27
  • S1 117.72
  • S2 112.68
  • S3 110.17

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Curis Lifesciences manufactures pharmaceutical products with a specialization in ophthalmic sterile ointments. The company focuses on producing high-quality, compliant formulations for healthcare needs, supported by dedicated manufacturing capabilities and a growing presence in the domestic pharmaceutical market.

Curis Lifesciences Ltd has an operating revenue of Rs. 148.05 Cr. on a trailing 12-month basis. An annual revenue growth of 38% is outstanding, Pre-tax margin of 17% is great, ROE of 37% is exceptional. The company has a reasonable debt to equity of 46%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its key moving averages, around -0% and -0% from 50DMA and 200DMA. It needs to stay above these levels to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 17% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 96 which is a GREAT score indicating consistency in earnings, a RS Rating of 47 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C which is evident from recent supply seen, Group Rank of 67 indicates it belongs to a poor industry group of Medical-Ethical Drugs and a Master Score of C is fair but needs to improve. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Curis Lifesciences Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-12-04 Quarterly Results

Curis Lifesciences F&O

Curis Lifesciences Shareholding Pattern

68.03%
0.11%
2.93%
0.11%
13.98%
14.84%

About Curis Lifesciences

  • NSE Symbol
  • CURIS
  • BSE Symbol
  • Chairman & Managing Director
  • Mr. Dharmesh Dasharathbhai Patel
  • ISIN
  • INE1BZN01016

Similar Stocks to Curis Lifesciences

Curis Lifesciences FAQs

Curis Lifesciences share price is ₹118 As on 20 January, 2026 | 16:43

The Market Cap of Curis Lifesciences is ₹95.6 Cr As on 20 January, 2026 | 16:43

The P/E ratio of Curis Lifesciences is 15.7 As on 20 January, 2026 | 16:43

The PB ratio of Curis Lifesciences is 4.5 As on 20 January, 2026 | 16:43

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23